Organon Acquisition Expands Sun Pharma's Reach
Sun Pharmaceutical Industries Limited announced a definitive agreement to acquire Organon & Co. for US$ 11.75 billion. This all-cash transaction values Organon at US$ 14.00 per share.
Spun off from Merck in 2021, Organon is a global healthcare company with a portfolio of over 70 products in women’s health and general medicines. These products are available in 140 countries, including major markets such as the U.S., Europe, and China.
Aligned with Sun Pharma‘s strategy to grow its innovative medicines business, this acquisition strengthens the company’s portfolio and global scale, fostering long-term value creation.
Six manufacturing facilities in the European Union and emerging markets support Organon’s global footprint, enhancing its scale and reach. This acquisition allows Sun Pharma to enter the biosimilars market as a top 10 global player.
Sun Pharma’s Executive Chairman, Dilip Shanghvi, stated, “This transaction offers an opportunity for Sun Pharma to build on its vision of Reaching People and Touching Lives. Organon’s portfolio and global reach complement our strengths.”
Sun Pharma aims to become one of the top 25 global pharmaceutical companies with combined revenue of US$ 12.4 billion following the transaction. The company will also lead in established brands and branded generics.
Strategic Synergies and Growth
Managing Director Kirti Ganorkar emphasised synergies and revenue growth, stating, “Our immediate priorities will be business continuity, disciplined integration, and responsible value creation.”
With the acquisition, Sun Pharma will operate in 150 countries, including 18 large markets generating over US$ 100 million in revenues each. This growth is expected to nearly double the company’s EBITDA and cash flow, aiding in reducing post-transaction Net Debt/EBITDA to 2.3x.
Entering the biosimilars market positions Sun Pharma as the 7th largest global player. Focus on innovative medicines will increase the revenue share to 27%.
Approval from the Boards of Directors of both Sun Pharma and Organon has been secured. The deal is pending regulatory and stockholder approvals, with closure anticipated in early 2027.
Last updated: 27 April 2026, 11:34 am
